These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 18386629

  • 1. [Fulminant strongyloidiasis successfully treated by subcutaneous ivermectin: an autopsy case].
    Takashima N, Yazawa S, Ishihara A, Sugimoto S, Shiomi K, Hiromatsu K, Nakazato M.
    Rinsho Shinkeigaku; 2008 Jan; 48(1):30-5. PubMed ID: 18386629
    [Abstract] [Full Text] [Related]

  • 2. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis.
    Turner SA, Maclean JD, Fleckenstein L, Greenaway C.
    Am J Trop Med Hyg; 2005 Nov; 73(5):911-4. PubMed ID: 16282302
    [Abstract] [Full Text] [Related]

  • 3. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin.
    Marty FM, Lowry CM, Rodriguez M, Milner DA, Pieciak WS, Sinha A, Fleckenstein L, Baden LR.
    Clin Infect Dis; 2005 Jul 01; 41(1):e5-8. PubMed ID: 15937753
    [Abstract] [Full Text] [Related]

  • 4. Salvage treatment of disseminated strongyloidiasis in an immunocompromised patient: therapy success with subcutaneous ivermectin.
    Moura EB, Maia Mde O, Ghazi M, Amorim FF, Pinhati HM.
    Braz J Infect Dis; 2012 Jul 01; 16(5):479-81. PubMed ID: 22975175
    [Abstract] [Full Text] [Related]

  • 5. Minimal change nephrotic syndrome in a patient with strongyloidiasis.
    Miyazaki M, Tamura M, Kabashima N, Serino R, Shibata T, Miyamoto T, Furuno Y, Nishio T, Ohara J, Sakurai T, Otsuji Y.
    Clin Exp Nephrol; 2010 Aug 01; 14(4):367-71. PubMed ID: 20224878
    [Abstract] [Full Text] [Related]

  • 6. Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.
    Ashida C, Kinoshita K, Nozaki Y, Funauchi M.
    BMC Infect Dis; 2020 Jul 02; 20(1):470. PubMed ID: 32615937
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature.
    Barrett J, Broderick C, Soulsby H, Wade P, Newsholme W.
    J Antimicrob Chemother; 2016 Jan 02; 71(1):220-5. PubMed ID: 26462990
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Fatal outcome of a hyperinfection syndrome despite successful eradication of Strongyloides with subcutaneous ivermectin.
    Hauber HP, Galle J, Chiodini PL, Rupp J, Birke R, Vollmer E, Zabel P, Lange C.
    Infection; 2005 Oct 02; 33(5-6):383-6. PubMed ID: 16258873
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous manifestations of Strongyloides stercoralis hyperinfection in an HIV-seropositive patient.
    Martin SJ, Cohen PR, MacFarlane DF, Grossman ME.
    Skinmed; 2011 Oct 02; 9(3):199-202. PubMed ID: 21675505
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.